Close Menu

NEW YORK – Cancer detection technology firm StageZero Life Sciences said on Thursday it has raised C$2.7 million ($2.1 million) of its targeted C$3.7 million private placement financing round.

The company, which has offices in Richmond Hill, Ontario, added that it expects the round to close by July 19 and the private placement is fully subscribed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.